Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc Logo
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 89.09 USD 0.99% Market Closed
Market Cap: 9.4B USD
Have any thoughts about
Intra-Cellular Therapies Inc?
Write Note

Intra-Cellular Therapies Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Intra-Cellular Therapies Inc
Net Income (Common) Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Net Income (Common)
-$86.4m
CAGR 3-Years
31%
CAGR 5-Years
10%
CAGR 10-Years
-14%
Johnson & Johnson
NYSE:JNJ
Net Income (Common)
$14.7B
CAGR 3-Years
-6%
CAGR 5-Years
1%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Net Income (Common)
-$7.3B
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Net Income (Common)
$4.3B
CAGR 3-Years
-40%
CAGR 5-Years
-23%
CAGR 10-Years
-9%
Merck & Co Inc
NYSE:MRK
Net Income (Common)
$12.1B
CAGR 3-Years
19%
CAGR 5-Years
5%
CAGR 10-Years
8%
Eli Lilly and Co
NYSE:LLY
Net Income (Common)
$8.4B
CAGR 3-Years
12%
CAGR 5-Years
1%
CAGR 10-Years
12%

See Also

What is Intra-Cellular Therapies Inc's Net Income (Common)?
Net Income (Common)
-86.4m USD

Based on the financial report for Sep 30, 2024, Intra-Cellular Therapies Inc's Net Income (Common) amounts to -86.4m USD.

What is Intra-Cellular Therapies Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-14%

Over the last year, the Net Income (Common) growth was 44%. The average annual Net Income (Common) growth rates for Intra-Cellular Therapies Inc have been 31% over the past three years , 10% over the past five years , and -14% over the past ten years .

Back to Top